Date: 2015-03-02
Type of information: Financing round
Company: GenePOC (Canada)
Investors: Debiopharm Diagnostics (Switzerland) Emerillon Capital (Canada)
Amount: undisclosed
Funding type: financing round
Planned used: Located in Québec city, Canada, GenePOC Inc. is a privately owned company that develops cost-effective and rapid molecular devices to detect genes at Point-of-Care. GenePOC has developed a simple and integrated portable instrument for the prevention and early detection of infectious diseases based on a unique centripetal technology platform.
Others: * On January 13, 2015, Debiopharm Diagnostics, part of Debiopharm Group™, announced that the company is the lead investor in GenePOC, who are developing a highly innovative, low cost and quick MDx (Molecular Diagnostics) platform. Debiopharm Diagnostics led this investment round together with Emerillon Capital and will become the largest shareholder in GenePOC.
Therapeutic area: Infectious diseases - Diagnostic
